Market Research Report

Global Oncolytic Virus Therapy Market Research Report: Forecast (2022-2027)

Oncolytic Virus Therapy Market - By Therapy (IMLYGIC {Talimogene Laherparepvec}, Oncorine, RIGVIR Immunotherapy, Onyx-15, Reolysin), By Application (Solid Tumor [Breast Cancer, Pro...state Cancer, Lung Cancer, Glioblastoma/Glioblastoma Multiforme], Melanoma, Hematological Malignancies [Lymphoma, Leukemia, Myeloma]), By Type of Virus (Genetically Engineered Oncolytic Virus [Herpes Simplex Virus{HSV}, Adenovirus, Vaccinia Virus], Oncolytic Wild Type of Viruses [Myxoma, Vesicular Stomatitis Virus {VSV}, Newcastle Disease Virus {NDV}, Reovirus {Respiratory Enteric Orphan Virus}]), By End User (Hospitals, Clinics, Patients, Cancer Research Institutes) and Others Read more

  • Healthcare
  • Nov 2021
  • Pages 221
  • Report Format: PDF, Excel, PPT

US Reciprocal Tax Impact on Markets: Stay Informed with Expert Insights and Real-Time Updates

Oncolytic Viruses (OVs) are genetically engineered or naturally occurring viruses that selectively target & kill cancer cells without harming the normal tissues. This therapy is a new therapeutic procedure to treat cancer patients and has presented promising outcomes worldwide.

According to MarkNtel Advisors, the Global Oncolytic Virus Therapy Market is projected to grow at a CAGR of around 20.3% during the forecast period i.e. 2022-27. The market is driven primarily by the mounting prevalence of cancer worldwide and the surging number of clinical trials & R&D investments for cancer therapies.

Moreover, the burgeoning focus of the governments in both developed & emerging countries on reducing mortality & morbidity rates by conducting various awareness campaigns toward encouraging people to opt for early diagnosis has increased the patient pool of oncolytic virus therapies. Hence, in the coming years, the global market is projected to significantly grow and create lucrative growth opportunities for the leading players in the market.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR (2022-2027) 20.3%
Regions Covered North America: USA, Canada, Mexico
Europe: Germany, UK, France, Italy, Spain
Asia-Pacific: China, India, Japan, Australia
South America: Brazil, and Argentina
Middle East & Africa:  UAE, Saudi Arabia, South Africa
Key Companies Profiled Amgen Inc., Daiichi Sankyo Company Limited, DNAtrix, Genelux Corporation, Oncolytics Biotech Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co. Ltd., SillaJen Inc., Sorrento Therapeutics Inc., Takara Bio Inc., Lokon Pharma AB, VCN Biosciences, ViroCure Inc., Viralytics Ltd. (Merck & Co. Inc.)
Unit Denominations USD Million/Billion

 

Impact of Covid-19 on the Global Oncolytic Virus Therapy Market

  • The Covid-19 pandemic in 2020 brought the entire healthcare sector under extensive pressure.
  • It made many nations realize that their healthcare infrastructure wasn't prepared or sufficient enough to handle such a large influx of very sick Covid-19 patients.
  • Overcrowded emergency rooms, which were initially feared, turned into reality across many communities.
  • However, the mounting need for an effective vaccine against the coronavirus and continued R&D on using Oncolytic Virus therapies to fight the Covid-19 infection helped the market remain steady amidst the crisis.



Market Segmentation

Based on Application, the Global Oncolytic Virus Therapy Market segments into:

  • Solid Tumor
    • Breast Cancer
    • Prostate Cancer
    • Lung Cancer
    • Glioblastoma/Glioblastoma Multiforme
  • Melanoma
  • Hematological Malignancies

Of them all, Melanoma is anticipated to dominate the Global Oncolytic Virus Therapy Market in the coming years. It owes to the increasing cases of this skin cancer among people arising from melanocytes. The early-stage lesions might be curative through complete surgical excision, yet the metastatic melanoma remains therapeutically challenging.

Oncolytic Virus Therapy uses the native or attenuated live viruses to selectively eliminate the melanoma cells & induce systemic tumor-specific immune responses. The treatment for Melanoma has evolved rapidly in recent years and has used intratumoral injections. The first FDA-approved oncolytic virus therapy was in 2015, called Talimogene Laherparepvec (T-VEC). This virus displays improvements in patients with a durable response rate with advanced Melanoma.

On the other hand, Oncolytic Virus Therapy for Breast Cancer is expected to display promising outcomes in the coming years. Breast cancer is the second most common cause of death from cancer in the United States after lung cancer. According to the American Society of Clinical Oncology (ASCO), currently, there are more than 3.8 million women diagnosed with breast cancer in the US. 

Current treatments to cure metastatic breast cancer are insufficient and often incur severe side effects that worsen patients’ life quality. Hence, the need for oncolytic viruses as immunotherapeutics & their rational combination with other therapeutic approaches for the optimal treatment of breast cancer is rising rapidly, states MarkNtel Advisors in their research report, “Global Oncolytic Virus Therapy Market Analysis, 2021.”

Regional Landscape

Based on the Geography, the Global Oncolytic Virus Therapy Market expands across:

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Of them all, North America is projected to attain the largest market share during 2022-27, mainly due to its extensive & superior healthcare infrastructure, coupled with improvised reimbursement policies across various countries. Additionally, the well-established research environment for biotechnologies in the region also significantly contributes to the overall market growth. Besides, the presence of the leading healthcare providers, especially in countries like the US & Canada, coupled with their active participation in the R&D of cancer therapy through massive investments, are other crucial aspects expected to drive the regional market in the coming years.

Recently, Amgen Inc. has received approval from the US Food & Drug Administration (FDA) for a Biologics License Application for IMLYGIC (T-Vec) Therapy. It is principally for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma that is recurrent after the initial surgery.

Market Dynamics:

Key Drivers

  • Increasing technological advancements in cancer treatments & the development of new therapies
  • Growing adoption of advanced therapeutic options & rising cancer cases
  • Research & Development initiatives & investments by healthcare providers

Possible Restraints

  • High costs of OV therapy imposing financial burden for low & middle-income cancer patients
  • Challenges in the research & development of safe & effective therapies
  • Limited availability of drugs

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Oncolytic Virus Therapy Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Oncolytic Virus Therapy Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Oncolytic Virus Therapy Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Oncolytic Virus Therapy Market study?

Don't Need a Global Report? Focus on reports for specific countries and regions

Frequently Asked Questions

   A. The Global Oncolytic Virus Therapy Market is likely to grow at a CAGR of around 20.3% in the coming period of 2022-27.

   A. Lung Cancer & Breast Cancer are the most likely to maintain their significant market share during the coming period.

   A. Increasing technological advancements in cancer treatments & the development of new therapies shall prominently drive the Global Oncolytic Virus Therapy Market through 2027.

   A. The Global Oncolytic Virus Therapy Market observed a considerable surge in recent years and is likely to continue the same trend in the coming years, owing to the consistent advancements in developing new therapies for cancer patients.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. Global Oncolytic Virus Therapy Market Policies, Regulations, and Product Standards
  5. Global Oncolytic Virus Therapy Market Value Chain Analysis
  6. Global Oncolytic Virus Therapy Market Trends & Developments
  7. Global Oncolytic Virus Therapy Market Dynamics
    1. Growth Drivers
    2. Challenges
  8. Global Oncolytic Virus Therapy Market Hotspot & Opportunities
  9. Global Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy
        1. IMLYGIC (Talimogene Laherparepvec)- Market Size & Forecast 2020-2030, USD Million
        2. Oncorine- Market Size & Forecast 2020-2030, USD Million
        3. RIGVIR Immunotherapy- Market Size & Forecast 2020-2030, USD Million
        4. Onyx-15- Market Size & Forecast 2020-2030, USD Million
        5. Reolysin- Market Size & Forecast 2020-2030, USD Million   
      2. By Application
        1. Solid Tumor- Market Size & Forecast 2020-2030, USD Million
          1. Breast Cancer- Market Size & Forecast 2020-2030, USD Million
          2. Prostate Cancer- Market Size & Forecast 2020-2030, USD Million
          3. Lung Cancer- Market Size & Forecast 2020-2030, USD Million
          4. Glioblastoma/Glioblastoma Multiforme- Market Size & Forecast 2020-2030, USD Million
        2. Melanoma- Market Size & Forecast 2020-2030, USD Million
        3. Hematological Malignancies- Market Size & Forecast 2020-2030, USD Million
          1. Lymphoma- Market Size & Forecast 2020-2030, USD Million
          2. Leukemia- Market Size & Forecast 2020-2030, USD Million
          3. Myeloma- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus
        1. Genetically Engineered Oncolytic Virus- Market Size & Forecast 2020-2030, USD Million
          1. Herpes Simplex Virus(HSV)- Market Size & Forecast 2020-2030, USD Million
          2. Adenovirus- Market Size & Forecast 2020-2030, USD Million
          3. Vaccinia Virus- Market Size & Forecast 2020-2030, USD Million
        2. Oncolytic Wild Type of Viruses- Market Size & Forecast 2020-2030, USD Million
          1. Myxoma- Market Size & Forecast 2020-2030, USD Million
          2. Vesicular Stomatitis Virus (VSV)- Market Size & Forecast 2020-2030, USD Million
          3. Newcastle Disease Virus (NDV)- Market Size & Forecast 2020-2030, USD Million
          4. Reovirus (Respiratory Enteric Orphan Virus)- Market Size & Forecast 2020-2030, USD Million
      4. By End User
        1. Hospitals- Market Size & Forecast 2020-2030, USD Million
        2. Clinics- Market Size & Forecast 2020-2030, USD Million
        3. Patients- Market Size & Forecast 2020-2030, USD Million
        4. Cancer Research Institutes- Market Size & Forecast 2020-2030, USD Million
      5. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East and Africa
        5. Asia-Pacific
      6. By Company
        1. Company Revenue Shares
        2. Competitor Characteristics
  10. North America Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy- Market Size & Forecast 2020-2030, USD Million
      2. By Application- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
      4. By End User- Market Size & Forecast 2020-2030, USD Million
      5. By Country
        1. The US
        2. Canada
        3. Mexico
    3. The US Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    4. Canada Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    5. Mexico Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
  11. South America Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy- Market Size & Forecast 2020-2030, USD Million
      2. By Application- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
      4. By End User- Market Size & Forecast 2020-2030, USD Million
      5. By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    3. Brazil Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    4. Argentina Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
  12. Europe Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy- Market Size & Forecast 2020-2030, USD Million
      2. By Application- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
      4. By End User- Market Size & Forecast 2020-2030, USD Million
      5. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    3. The UK Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    4. Germany Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    5. France Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    6. Italy Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    7. Spain Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
        2. By End User- Market Size & Forecast 2020-2030, USD Million
  13. Middle East & Africa Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy- Market Size & Forecast 2020-2030, USD Million
      2. By Application- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
      4. By End User- Market Size & Forecast 2020-2030, USD Million
      5. By Country
        1. Saudi Arabia
        2. The UAE
        3. South Africa
        4. Rest of Middle East & Africa
    3. Saudi Arabia Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    4. The UAE Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    5. South Africa Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
  14. Asia Pacific Oncolytic Virus Therapy Market Outlook, 2020-2030F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Therapy- Market Size & Forecast 2020-2030, USD Million
      2. By Application- Market Size & Forecast 2020-2030, USD Million
      3. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
      4. By End User- Market Size & Forecast 2020-2030, USD Million
      5. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. Rest of Asia Pacific
    3. China Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    4. Japan Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    5. India Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
    6. Australia Oncolytic Virus Therapy Market Outlook, 2020-2030F
      1. Market Size & Outlook
        1. By Revenues (USD Million)
      2. Market Share & Outlook
        1. By Therapy- Market Size & Forecast 2020-2030, USD Million
        2. By Type of Virus- Market Size & Forecast 2020-2030, USD Million
  15. Global Oncolytic Virus Therapy Market Key Strategic Imperatives for Success & Growth
  16. Competition Outlook
    1. Company Profiles
      1. Amgen Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Daiichi Sankyo Company Limited
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      3. DNAtrix
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Genelux Corporation
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Oncolytics Biotech Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      6. PsiOxus Therapeutics
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      7. RIGVIR Ltd.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Shanghai Sunway Biotech Co. Ltd.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      9. SillaJen Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Sorrento Therapeutics Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      11. Takara Bio Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      12. Lokon Pharma AB
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      13. VCN Biosciences
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      14. ViroCure Inc.
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      15. Viralytics Ltd. (Merck & Co. Inc.)
        1. Business Description
        2. Service Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      16. Others
  17. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Request Sample Talk to our Consultant Request Customization
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Related Reports